<DOC>
	<DOCNO>NCT00215657</DOCNO>
	<brief_summary>An Open-Label , Multi-Center , Extension Study Investigating Long-Term Safety Tolerability Repeat Doses FE200486 Prostate Cancer Patients</brief_summary>
	<brief_title>Extension Study Investigating Long-Term Safety Tolerability Repeat Doses FE200486 Prostate Cancer Patients</brief_title>
	<detailed_description>Degarelix FDA regulate time trial . After completion trial degarelix approve FDA thus FDA regulate intervention ( FDA regulate intervention therefore tick `` YES '' ) . The data include participant main study ( FE200486 CS07 ; NCT00818623 ) extension study FE200486 CS07A .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males age 18 Histologically proven adenocarcinoma prostate ( stage ) endocrine treatment indicate ( except neoadjuvant hormonal therapy ) Has complete Study FE200486 CS07 Has meet withdrawal criterion Visit 9 ( day 28 ) Study FE200486 CS07</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>